Eli Lilly Tops $1 Trillion Valuation After 28.3% Weight Loss Data, Gains CVS Coverage
LLY•Eli Lilly surpassed a $1 trillion market cap after shares rallied over 25% since March lows, driven by blockbuster phase 3 data showing Reta patients lost 28.3% of body weight. CVS Health will cover Zepbound from October 1 and Foundayo from June 1, expanding patient access to Lilly’s obesity treatments.
1. Market Capitalization Surge
Eli Lilly closed at a record high above a $1 trillion valuation on May 29, driven by a 25% rally since the March 30 low and a 400% gain over the past five years.
2. Reta Phase 3 TRIUMPH-1 Results
Retatrutide, nicknamed Reta, delivered phase 3 TRIUMPH-1 results showing patients on the highest dose lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, while over 45% of patients achieved at least 30% weight loss—a benchmark linked to bariatric surgery.
3. Expanded Insurance Coverage
CVS Health will add coverage for Zepbound on October 1 and for Foundayo on June 1, reversing prior plan exclusions and making both Lilly obesity treatments co-preferred with competitors, potentially boosting prescription uptake.
4. Broader Market Impact
Investors view Lilly’s GLP-1 platform extending into obesity as a growth engine, with ripple effects on packaged food and retail stocks, while chart watchers eye a breakout above the $1,100 level to sustain the bull trend.
